| Code | 8029D | ||||||||||
| MA number | 44/0154/21-S | ||||||||||
| Product Form: | tbl 120x250 mg (fľ.HDPE) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 30 | ||||||||||
| Container: | bottle HDPE | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 28.07.2021 |
| Validity: | 28.07.2026 |
| SPC: |
SPC_Abiraterone medac 250 mg tablety_07_2021.pdf
|
| PIL: |
PIL_Abiraterone medac 250 mg tablety_04.2022.pdf
|
| Safety feature | Yes |
| Data update: | 10.08.2021 |
